Drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp has demonstrated high response rates in patients with blastic plasmacytoid ...
Nov 14, 2018
0
3